Revolution Medicines secured a landmark FDA approval for daraxonrasib (Rasonque), a once-daily oral pan-RAS inhibitor for pancreatic ductal adenocarcinoma. Analysts characterized the regulatory decision as an inflection for a notoriously difficult cancer, with rapid uptake potential for a new RAS-targeting category. Roche also advanced the diagnostic stack supporting oncology precision by obtaining expanded FDA approval for tests tied to Jazz Pharmaceuticals’ Ziihera, extending HER2 status assessment to metastatic gastroesophageal and esophageal cancers. The combination of a new targeted therapy approval and broader companion diagnostic coverage reflects a coordinated push to match patients to RAS and HER2-directed regimens.